<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Decreasing Glioma Secondary Mutations to Delay Tumor Recurrence

Temozolomide-treated glioma patients often have recurrent tumors, which are linked to secondary mutations detected in the RB and AKT-mTOR signaling pathways.